HENLIUS's biosimilar HLX11 for patritumab has received a positive review opinion
HENLIUS (02696.HK) announced that recently, its self-developed biosimilar drug HLX11, a pertuzumab biosimilar, received a positive review opinion from the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP), recommending the approval of the marketing authorization application for HLX11. The CHMP's review opinion will be submitted to the European Commission, which will make a final review decision in the next 2-3 months
Source: AASTOCKS The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments